Clinical trial
A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)
NCT02716805 is registered in ClinicalTrials.gov with Ludwig Institute for Cancer Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)
- Lead sponsor
- Ludwig Institute for Cancer Research
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 13, 2016
- Completion date
- February 16, 2018
- Enrollment
- 6 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.